SequelSEC

INTELLIGENT BIO SOLUTIONS INC. INBS

Surgical & Medical Instruments & Apparatus · CIK 0001725430 · Fiscal year ends 0630

AnnualQuarterlyTTM
Revenue
$4.22M
Fiscal year ended 2026-06-30
Operating income
-$12.61M
Fiscal year ended 2026-06-30
Free cash flow
-$12.05M
Fiscal year ended 2026-06-30

INTELLIGENT BIO SOLUTIONS INC. (INBS) reported revenue of $4.22M and net income of -$12.43M for the fiscal year ended 2026-06-30. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from INTELLIGENT BIO SOLUTIONS INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

INTELLIGENT BIO SOLUTIONS INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-30
Revenue$4.22M$3.05M$3.11M$1.26M$437.15K$1.98M$188.74K
Cost of revenue$2.17M$1.81M$1.69M$930.20KUnavailableUnavailableUnavailable
Gross profit$2.05M$1.25M$1.43M$326.67KUnavailableUnavailableUnavailable
Operating income-$12.61M-$10.68M-$10.28M-$12.60M-$8.34M-$5.57M-$2.86M
Net income-$12.43M-$10.57M-$10.16M-$10.63M-$8.31M-$7.04M-$3.16M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 1.47MUnavailableshares 1.59MUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailable-$7.06M-$3.19M
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-8.44$-20.04$-6.38$-127.00$-11.33UnavailableUnavailable
Selling, general & administrative$10.50M$8.92MUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$10.50M$8.92M$9.26M$8.03M$4.92M$3.36M$2.20M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

INTELLIGENT BIO SOLUTIONS INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-30
Cash & equivalents$3.99M$1.02M$6.30M$1.54M$8.24M$12.57M$427.27K
Total assets$11.94M$8.25M$13.78M$10.35M$12.35M$21.86M$2.48M
Current assets$7.10M$4.14M$8.53M$3.86M$10.87M$18.21M$2.34M
Total liabilities$6.65M$5.44M$5.60M$6.67M$5.81M$6.85M$7.69M
Current liabilities$4.93M$5.35M$5.45M$5.88M$4.66M$3.68M$7.69M
Total equity incl. NCI$5.29M$2.81M$8.18M$3.69M$6.55M$15.01M-$5.21M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$418.58K$635.22K$777.54K$979.91KUnavailableUnavailableUnavailable
Accounts receivable$848.46K$594.61K$429.70K$293.86KUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$712.45K$897.26KUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

INTELLIGENT BIO SOLUTIONS INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-30
Operating cash flow-$11.93M-$9.68M-$9.57M-$7.38M-$3.36M-$11.30M-$498.62K
Capital expenditures$125.73K$231.84K$221.43KUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$85.57K-$231.84K-$221.43K-$694.14K-$880.22KUnavailable-$14.00K
Financing cash flow$14.98M$4.60M$14.56M$1.44MUnavailable$23.40M$733.86K
Net change in cash$2.97M-$5.28M$4.77M-$6.70M-$4.34M$12.15M$229.33K
Stock-based compensation$195.21K$238.04K$230.50K$260.00KUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$1.16M$1.21M$974.36K$814.48KUnavailableUnavailableUnavailable

Derived

INTELLIGENT BIO SOLUTIONS INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302024-06-302023-06-302022-06-302021-06-302020-06-30
Free cash flow-$12.05M-$9.91M-$9.79MUnavailableUnavailableUnavailableUnavailable
Gross margin48.6%40.8%45.8%26.0%UnavailableUnavailableUnavailable
Operating margin-299.1%-349.8%-330.5%-1002.1%Unavailable-281.4%-1513.7%
FCF margin-285.9%-324.6%-314.7%UnavailableUnavailableUnavailableUnavailable
SBC / revenue4.6%7.8%7.4%20.7%UnavailableUnavailableUnavailable
Current ratio1.44x0.77x1.57x0.66x2.33x4.94x0.30x
Revenue YoY growth38.1%-1.9%147.6%187.5%-77.9%949.3%Unavailable
Net margin-294.9%-346.2%-326.4%-845.9%Unavailable-355.3%-1676.2%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenue3.0%7.6%7.1%UnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open INBS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-K · Filed 2026-08-19View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-Q · Filed 2026-02-12View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-K · Filed 2025-08-15View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

ADGM AEMD ALUR AMIX ANGO ANIK AORT APYX ARAY ATEC ATRC AURX

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.